<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298463</url>
  </required_header>
  <id_info>
    <org_study_id>146(A)PO18530</org_study_id>
    <nct_id>NCT04298463</nct_id>
  </id_info>
  <brief_title>Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI</brief_title>
  <acronym>REDS</acronym>
  <official_title>Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hippocrates Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to collect the data on the effectiveness of dalbavancin in terms of&#xD;
      save of hospitalization days on patients treated between June 2017 and June 2019 in two&#xD;
      countries (Italy and Greece) vs the other Standards of care of the same class (SoC; i.v. lipo&#xD;
      and glycopeptides) in a real-life context.&#xD;
&#xD;
      Time to discharge from the start of therapy for ABSSSI in the hospital context will be&#xD;
      assessed and all relevant data available on patient management, clinical, microbiological and&#xD;
      safety outcomes during hospitalization and in the follow-up visits up to 30 days from&#xD;
      discharge will be collected and evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute bacterial skin and skin structure infections (ABSSSI), formally referred to as&#xD;
      complicated skin and soft tissue infections, include infections such as&#xD;
      cellulitis/erysipelas, wound infection, and major cutaneous abscess and have a minimum lesion&#xD;
      surface area of approximately 75 cm2. The regulatory definitions of major abscess,&#xD;
      cellulitis, and wound infection may not align with practice-based criteria. Common bacterial&#xD;
      pathogens causing ABSSSI are Streptococcus pyogenes and Staphylococcus aureus including&#xD;
      Methicillin-Resistant Staphylococcus Aureus (MRSA). Less common causes include other&#xD;
      Streptococcus species, Enterococcus faecalis, or Gram-negative bacteria.&#xD;
&#xD;
      Increasing dramatically in incidence, a challenging medical problem associated with high&#xD;
      direct and indirect costs has been highlighted for both the medical system and society.&#xD;
&#xD;
      Over the last decade, there was a witnessed a dramatic increase in the incidence of community&#xD;
      acquired skin infections, an increasing proportion of which are a consequence of MRSA,&#xD;
      reinforcing the need for new and effective antibacterial therapies in this disease.&#xD;
&#xD;
      In this context, research has been promoted to develop new antibiotics capable to fight MRSA,&#xD;
      the most common multi-drug-resistant Gram+ bacterium in Europe, and to overcome the&#xD;
      limitations of the most widely used antibiotics, such as vancomycin, teicoplanin, and β-&#xD;
      lactams. These new antibiotics (lipoglycopeptides and new oxazolidinones) have innovative&#xD;
      characteristics that make them interesting for the specific treatment of ABSSSIs. Dalbavancin&#xD;
      is one of these new antibiotics. Dalbavancin is a lipoglycopeptide with activity against&#xD;
      Grampositive organisms, including MRSA, through interference with bacterial cell wall&#xD;
      formation by preventing cross-linking of peptidoglycans. Dalbavancin has a distinctive&#xD;
      pharmacokinetic profile, with a terminal half-life of 14.4 days, which allows for infrequent&#xD;
      or even single intravenous dosing.&#xD;
&#xD;
      This new long-acting antibiotic represents a potential opportunity for early discharge. This&#xD;
      approach could profoundly modify the management of these infections by reducing or in some&#xD;
      cases eliminating hospitalization costs and risks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Actual">May 5, 2021</completion_date>
  <primary_completion_date type="Actual">May 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time of discharge from any ward of the hospital,</measure>
    <time_frame>From baseline to discharge, an average of 4 weeks</time_frame>
    <description>Time of discharge is calculated as the time elapsed from the beginning of antibiotic therapy (baseline) until discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the recorded signs and symptoms</measure>
    <time_frame>From the hospital admission until 30 days from discharge</time_frame>
    <description>Evaluation of local signs of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological evaluation</measure>
    <time_frame>From the hospital admission until 30 days from discharge</time_frame>
    <description>Eradication of the Gram Positive pathogens identified at baseline (MIC assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term follow-up</measure>
    <time_frame>90 days from discharge</time_frame>
    <description>Assessment for recurrence of ABSSSI.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">184</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infection</condition>
  <arm_group>
    <arm_group_label>COHORT A: dalbavancin</arm_group_label>
    <description>Patients hospitalized for at teast two days affected by ABSSSI and treated with dalbavancin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT B: lipo and glyco-peptid drugs</arm_group_label>
    <description>Patients hospitalized for at teast two days affected by ABSSSI and treated with vancomycin, teicoplanin or daptomycin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xydalba</intervention_name>
    <description>Drugs were administered i.v.</description>
    <arm_group_label>COHORT A: dalbavancin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vancomycin, teicoplanin or daptomycin</intervention_name>
    <description>Drugs were administered i.v.</description>
    <arm_group_label>COHORT B: lipo and glyco-peptid drugs</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include patients hospitalized for at least 2 days with evidence&#xD;
        of primary diagnosis of ABSSSI and treated with dalbavancin or other SoC of similar class&#xD;
        (i.v lipo and glycopeptides vancomycin, teicoplanin or daptomycin).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients ≥ of 18 years old&#xD;
&#xD;
          2. Patients hospitalized for at least 2 days with evidence of primary diagnosis of ABSSSI&#xD;
             of International Classification of Diseases (ICD) 9: - 681.XX (cellulitis and abscess&#xD;
             of finger and toe) -682.XX (other cellulitis and abscess) - 958.3X (post-traumatic&#xD;
             wound infection not elsewhere classified) - 998.5X (postoperative infection not&#xD;
             elsewhere classified); and corresponding code for ICD 10; and/or Diagnosis-related&#xD;
             group (DRG) 277; 278; 418 (for Italy), for cellulitis/erysipelas, wound infection,&#xD;
             major cutaneous abscess.&#xD;
&#xD;
          3. Patients treated with dalbavancin or other SoC of the same or similar class (i.v. lipo&#xD;
             and glycopeptides: teicoplanin, vancomycin, daptomycin) according to summary of&#xD;
             product characteristics (SmPC).&#xD;
&#xD;
          4. Patients treated with or without other chemotherapy to cover Gram- bacteria or&#xD;
             fungals.&#xD;
&#xD;
          5. Patients who gave their consent for personal data processing according to the local&#xD;
             regulation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with infected wound or ulcer (neoplastic, inflammatory and autoimmune&#xD;
             ulcers), animal bite&#xD;
&#xD;
          2. Patients with ulcer not colonized, discolored, odorous, pressure ulcer grade I, II,&#xD;
             III, or IV (according to NPUAP classification - Appendix A)&#xD;
&#xD;
          3. Patients with arteriopathies&#xD;
&#xD;
          4. Patients presenting or who have presented in the last 30 days before the&#xD;
             hospitalization the following infections:&#xD;
&#xD;
               -  diabetic foot infection (ICD9= 707.15; 249.8)&#xD;
&#xD;
               -  suspected or confirmed osteomyelitis (ICD9= 730.xx)&#xD;
&#xD;
               -  suspected or confirmed septic arthritis (ICD9= 711.00)&#xD;
&#xD;
               -  infective endocarditis (ICD9=421.0)&#xD;
&#xD;
               -  meningitis (ICD9=322.xx)&#xD;
&#xD;
               -  joint infection (ICD9= 711.00)&#xD;
&#xD;
               -  necrotizing fasciitis (ICD9=728.86)&#xD;
&#xD;
               -  gangrene (ICD9=785.4)&#xD;
&#xD;
               -  prosthetic joint infection or prosthetic implant/device infection (ICD9=996.66)&#xD;
&#xD;
          5. Patient with history of neutropenia or in treatment with immunosuppressants in the&#xD;
             last six months before the hospitalization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Alexandroupolis</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon University Hospital, Rimini 1, Chaidari, 124 62</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki AHEPA /</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Sant'Orsola Malpighi Unità Operativa di Malattie Infettive</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera per l'Emergenza Cannizzaro Unità Operativa Complessa di Malattie Infettive</name>
      <address>
        <city>Catania</city>
        <zip>95126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi SOD Malattie Infettive e Tropicali</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino - IRCCS Genova Clinica Malattie Infettive</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST MANTOVA Ospedale Carlo Poma di Mantova S.C. Malattie Infettive</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.S.S.T. GRANDE OSPEDALE METROPOLITANO NIGUARDA S.C. Malattie Infettive Dipartimento Medico Polispecialistico</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Federico II di Napoli Dipartimento di Medicina clinica e Chirurgia UOC Malattie Infettive</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova U.O.C. Malattie Infettive e Tropicali</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria della Misericordia Clinica Malattie Infettive Dipartimento di Medicina, Università Studi di Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Pisana Stabilimento di Cisanello U.O Malattie Infettive</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.R. San Carlo Struttura Interaziendale Complessa di Malattie Infettive</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e Scienza - Presidio Molinette SC Malattie Infettive</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABSSSI</keyword>
  <keyword>skin infections</keyword>
  <keyword>lipoglycopeptide,</keyword>
  <keyword>Gram-positive bacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
    <mesh_term>Dalbavancin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

